




| | | | |
|--------------------------|--|--------------------|--------------------|
| | | EMLc | ATC codes: J01DD01 |
| Indication | Other specified pneumonia | ICD11 code: CA40.Y | |
| INN | Cefotaxime | | |
| Medicine type | Chemical agent | | |
| Antibiotic groups | <div><div>W</div>WATCH</div> | | |
| List type | Core (EML) (EMLc) | | |
| Additional notes | 3rd generation cephalosporin of choice for use in hospitalized neonates. | | |
| Formulations | Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt) ; 500 mg in vial powder for injection (as sodium salt) ; 1 g in vial powder for injection (as sodium salt) ; 2 g in vial powder for injection (as sodium salt) | | |
| EML status history | First added in 2017 (TRS 1006) Changed in 2023 (TRS 1049) | | |
| Sex | All | | |
| Age | Also recommended for children | | |
| Therapeutic alternatives | The recommendation is for this specific medicine | | |
| Patent information | Patents have expired in most jurisdictions Read more about patents .  | | |
| Wikipedia | Cefotaxime  | | |
| DrugBank | Cefotaxime  | | |

Expert Committee recommendation

The Expert Committee recommended the inclusion of a new strength, child-friendly dispersible tablet formulation of amoxicillin + clavulanic acid (200 mg + 28.5 mg) as an Access group antibiotic on the core list of the EMLc for treatment of bacterial infections in children – specifically those infections for which amoxicillin + clavulanic acid is already recommended on the EMLc. The Committee noted that the 7:1 ratio of amoxicillin to clavulanic acid is associated with similar efficacy to the 4:1 ratio but has a reduced frequency of gastrointestinal adverse effects. The Committee endorsed the importance of age-appropriate formulations to better meet the dosing needs of children. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a new formulation of amoxicillin + clavulanic acid (dispersible tablet 250 mg + 62.5 mg) to the EMLc. - the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc.

EML recommendations: Other specified pneumonia

First choice

Second choice

HOSPITAL-ACQUIRED PNEUMONIA

piperacillin + tazobactam

amoxicillin + clavulanic acid

cefotaxime

ceftriaxone

